Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470326 | 0.90 | POLB (0.37) | ADORA2AGAAPOLBALDH1A1PKM | |
| SCHEMBL6465702 | 0.86 | ADORA2A (0.39) | ADORA2AALDH1A1PKMKMT2ASMN1; SMN2 | |
| SCHEMBL6468661 | 0.86 | BRAF (0.39) | ADORA2A | |
| Trifluoroacetic Acid SCHEMBL6470296 | 0.86 | GAA (0.36) | ADORA2AGAAPOLBALDH1A1PKM | |
| SCHEMBL6468693 | 0.85 | ADORA2A (0.38) | ADORA2AGAAPOLBALDH1A1PKM | |
| SCHEMBL6470468 | 0.85 | ADORA2A (0.39) | ADORA2AGAAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6468047 | 0.83 | POLB (0.38) | ADORA2AGAAPOLBALDH1A1PKM | |
| SCHEMBL6467457 | 0.83 | ALDH1A1 (0.36) | ADORA2AGAAPOLBALDH1A1PKM | |
| SCHEMBL6469516 | 0.81 | KMT2A (0.42) | GAAPOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6469269 | 0.80 | POLB (0.37) | ADORA2AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | ADORA2A 4250/4885GAA 232/4885POLB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.